SG Americas Securities
BBIO icon

SG Americas Securities’s BridgeBio Pharma BBIO Stock Holding History

SG Americas Securities’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Sell
38,554
-95,663
-71% -$6.7M ﹤0.01% 1327
2026
Q1 		$9.97M Buy
134,217
+54,400
+68% +$3.94M 0.01% 788
2025
Q4 		$6.11M Buy
79,817
+60,429
+312% +$3.97M 0.01% 1005
2025
Q3 		$1.01M Buy
19,388
+9,040
+87% +$441K ﹤0.01% 1452
2025
Q2 		$447K Buy
+10,348
New +$376K ﹤0.01% 1749
2024
Q4 		– Sell
-37,151
Closed -$946K – 3151
2024
Q3 		$946K Sell
37,151
-16,714
-31% -$439K ﹤0.01% 1125
2024
Q2 		$1.36M Buy
53,865
+47,578
+757% +$1.3M 0.01% 1151
2024
Q1 		$194K Buy
6,287
+2,545
+68% +$86.5K ﹤0.01% 1993
2023
Q4 		$151K Sell
3,742
-914
-20% -$27.4K ﹤0.01% 2408
2023
Q3 		$123K Buy
+4,656
New +$132K ﹤0.01% 2653
2023
Q2 		– Sell
-19,545
Closed -$324K – 2323
2023
Q1 		$324K Buy
+19,545
New +$228K ﹤0.01% 2071
2022
Q4 		– Sell
-21,316
Closed -$212K – 3064
2022
Q3 		$212K Sell
21,316
-100,995
-83% -$1.05M ﹤0.01% 2278
2022
Q2 		$1.11M Buy
122,311
+92,177
+306% +$771K 0.01% 1217
2022
Q1 		$306K Buy
30,134
+15,939
+112% +$164K ﹤0.01% 2189
2021
Q4 		$237K Sell
14,195
-11,142
-44% -$471K ﹤0.01% 2584
2021
Q3 		$1.19M Buy
25,337
+6,657
+36% +$357K 0.01% 1751
2021
Q2 		$1.14M Buy
18,680
+4,185
+29% +$239K 0.01% 1478
2021
Q1 		$893K Sell
14,495
-4,037
-22% -$264K ﹤0.01% 1631
2020
Q4 		$1.32M Buy
18,532
+3,374
+22% +$163K 0.01% 1363
2020
Q3 		$569K Sell
15,158
-5,040
-25% -$159K ﹤0.01% 1546
2020
Q2 		$659K Buy
20,198
+5,406
+37% +$165K 0.01% 1819
2020
Q1 		$429K Buy
14,792
+9,314
+170% +$289K ﹤0.01% 1960
2019
Q4 		$192K Buy
+5,478
New +$152K ﹤0.01% 2498
2019
Q3 		– Sell
-17,647
Closed -$476K – 2999
2019
Q2 		$476K Buy
+17,647
New +$481K ﹤0.01% 1916

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

SG Americas Securities's BBIO Position: Q2 2026 in Review

SG Americas Securities reduced its BridgeBio Pharma (BBIO) stake by 71% in Q2 2026, selling an estimated $6.7M and leaving 38,554 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1327.

SG Americas Securities first reported a position in BBIO in Q2 2019 and has held it in 24 quarters since. The position peaked at $9.97M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • SG Americas Securities held 38,554 shares of BridgeBio Pharma worth $2.87M as of Q2 2026.
  • SG Americas Securities sold 95,663 BridgeBio Pharma shares in Q2 2026, an estimated $6.7M.
  • BridgeBio Pharma made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1327 holding.
  • SG Americas Securities first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 24 quarters since.
  • SG Americas Securities's BridgeBio Pharma position peaked at $9.97M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.